Eloxx Pharmaceuticals, Inc. (ELOX): Operating Income
-$6.44M
Year ended 2025-12-31
-$11.88M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$6.44M | n/m | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | -$2.47M | n/m | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | -$17.29M | n/m | 2026-03-17, From 2023-01-01 |
| 2022-12-31 | -$34.42M | n/m | 2023-03-31, From 2022-01-01 |
| 2021-12-31 | -$66.02M | n/m | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | -$33.45M | n/m | 2022-03-30, From 2020-01-01 |
| 2019-12-31 | -$50.55M | n/m | 2022-03-30, From 2019-01-01 |
| 2018-12-31 | -$47.56M | n/m | 2021-03-12, From 2018-01-01 |
| 2017-12-31 | -$20.39M | n/m | 2020-03-06, From 2017-01-01 |
| 2016-12-31 | -$9.84M | n/m | 2019-03-14, From 2016-01-01 |
| 2015-12-31 | -$6.28M | n/a | 2018-03-16, From 2015-01-01 |
| No annual figure between 2014-06-30 and 2015-12-31. | |||
| 2014-06-30 | -$9.15M | n/m | 2016-10-13, From 2013-07-01 |
| 2013-06-30 | -$4.65M | n/m | 2015-10-09, From 2012-07-01 |
| 2012-06-30 | -$5.41M | n/m | 2014-09-29, From 2011-07-01 |
| 2011-06-30 | -$7.92M | n/c | 2013-09-11, From 2010-07-01 |
| 2010-06-30 | -$4.85M | n/a | 2012-10-26, From 2009-07-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | 2025-12-31 | -$6.44M | n/m |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $18.07M | n/m |
| Amgen Inc (AMGN) | 2025-12-31 | $9.08B | +25.1% |
| Repligen Corp (RGEN) | 2025-12-31 | $55.17M | n/m |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | -$1.14M | n/m |
| Bio-Techne Corp (TECH) | 2026-06-30 | $251.89M | +146.3% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$36.62M | n/m |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $10.02B | +503.0% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $340.99M | n/m |
Compare ELOX, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗